UNSPSC 51111870: Vapreotide

This classification denotes a somatostatin receptor agonist with the molecular formula C57H70N12O9S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2PK59M9GFF, chemically known as l-tryptophanamide, d-phenylalanyl-l-cysteinyl-l-tyrosyl-d-tryptophyl-l-lysyl-l-valyl-l-cysteinyl-, cyclic (2->7)-disulfide but generally known as vapreotide, which bears US NIH Compound Identifier 71306. European Medicines Agency schedules Vapreotide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00026MIG.

UNSPSC 51111870 Vapreotide is a Commodity code identifying a synthetic somatostatin analog pharmaceutical product. State and local governments procure vapreotide primarily through health systems, correctional medical departments, and public hospitals to treat acute variceal bleeding and other gastrointestinal conditions in inpatient and emergency settings. The drug is typically sourced through hospital formularies, group purchasing organizations (GPOs), and state Medicaid pharmacy networks rather than as a standalone procurement activity. Issuing bodies include state departments of health, county hospital systems, municipal medical facilities, and state correctional agencies; procurement vehicles range from standing pharmaceutical supply contracts to emergency medical acquisitions tied to broader hospital supply agreements.

The source provided contains no recent state and local contract opportunities or solicitations under this code. Without posted RFPs, RFQs, IFBs, or ITBs naming vapreotide as a line item or primary procurement objective, the geographic distribution and current market activity cannot be characterized. If vapreotide procurement occurs in your target jurisdictions, it likely flows through existing pharmaceutical supply contracts or GPO master agreements rather than through discrete, published solicitations. Direct outreach to state health procurement offices, hospital system pharmacy directors, and state Medicaid programs may surface indirect opportunities within broader drug-purchasing cycles.